MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ
61.43
-0.73
-1.17%
After Hours: 61.52 +0.09 +0.15% 18:03 08/13 EDT
OPEN
63.33
PREV CLOSE
62.16
HIGH
63.33
LOW
61.06
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
66.24
52 WEEK LOW
16.96
MARKET CAP
5.79B
P/E (TTM)
-124.0008
1D
5D
1M
3M
1Y
5Y
1D
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 1d ago
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
TipRanks · 1d ago
Travere Therapeutics Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 3d ago
Travere Therapeutics Price Target Raised to $78.00/Share From $68.00 by Evercore ISI Group
Dow Jones · 3d ago
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78
Benzinga · 3d ago
Weekly Report: what happened at TVTX last week (0803-0807)?
Weekly Report · 3d ago
Wall Street Analysts Are Neutral on Top Healthcare Picks
TipRanks · 4d ago
Travere Q2 Loss Widens Despite FILSPARI Sales Surge; Phase 4 SPARLIGHT Study Set To Begin In H2 '26
NASDAQ · 6d ago
More
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Webull offers Travere Therapeutics Inc stock information, including NASDAQ: TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.